Professors Linda Griffith and Feng Zhang along with Guillermo Ameer ScD ’99, Darrell Gaskin SM ’87, and Vamsi Mootha recognized for contributions to medical sciences, health care, and public health.
Exploring diversity among bacterial immune systems, McGovern Institute scientists uncovere a programmable system for precisely targeting and modifying RNA.
Researchers find RNA-guided enzymes are more diverse and widespread than previously believed.
Made of components found in the human body, the programmable system is a step toward safer, targeted delivery of gene editing and other molecular therapeutics.
Four times faster than conventional PCR methods, new RADICA approach is highly specific, sensitive, and resistant to inhibitors.
Novel method, developed by McGovern Institute researchers, may lead to safer, more efficient gene therapies.
Kytopen is speeding up both discovery and delivery of engineered cell therapies with its transformative Flowfect platforms.
KSQ Therapeutics uses technology created at MIT to study the role of every human gene in disease biology.
New, reversible CRISPR method can control gene expression while leaving underlying DNA sequence unchanged.
Scalable CRISPRi system from SMART allows scientists to identify and tackle causes of E. faecalis-related diseases and drug resistance.
Using CRISPR technology, researchers are tracking the lineage of individual cancer cells as they proliferate and metastasize in real-time.
Tiny microRNAs help destroy unwanted messenger RNAs in cells. New research finds how the body keeps them in check.
A CRISPR-based test developed at MIT and the Broad Institute can detect nearly as many cases as the standard Covid-19 diagnostic.
Collaborative research center funded by Lisa Yang and Hock Tan ’75 blends engineering and neuroscience to advance molecular tools for treating brain disorders.
Applied computational biology discoveries vastly expand the range of CRISPR’s access to DNA sequences.